HO-1 has been shown to reduce NLRP3 inflammasome activity in mice (32); it also reduces visceral fat accumulation, normalizes metabolic profiles, and prevents obesity, thereby reducing cardiovascular and renal complications (7, 33–35). Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.